Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cinaciguat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 2/20 | 0.62 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.62 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.62 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 7/20 | 0.45 |
| ▸ | RXRB | P28702 | 6/20 | 0.45 |
| ▸ | RXRG | P48443 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.43 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cinaciguat SCHEMBL2987188 | 0.99 | PTGER1 (0.61) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL13009539 | 0.98 | PTGER1 (0.61) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL2982959 | 0.96 | PTGER1 (0.57) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL13009831 | 0.95 | PTGER1 (0.56) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL29748782 | 0.95 | PTGER1 (0.53) | PTGER1PTGER4PTGER3PTGER2HTR1A | |
| SCHEMBL13009672 | 0.94 | PTGER1 (0.57) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL13009661 | 0.93 | PTGER1 (0.55) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL13009719 | 0.92 | PTGER1 (0.54) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL13009681 | 0.92 | PTGER1 (0.54) | PTGER1PTGER4PTGER3PTGER2RXRA | |
| SCHEMBL13009666 | 0.92 | PTGER1 (0.54) | PTGER1PTGER4PTGER3PTGER2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 764 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | AMGEN INC. (US) | 2026-05-28 | — | — | US | claimed |
| US-20250281485-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | UNIVERSITEIT MAASTRICHT (NL) | 2025-09-11 | — | — | US | claimed |
| US-20250205276-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE USING COMBINATION OF A NITRODILATOR AND A NITROGEN OXIDE COMPOUND | LOMA LINDA UNIVERSITY (US) | 2025-06-26 | — | — | US | claimed |
| EP-4511017-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | Universiteit Maastricht (NL) | 2025-02-26 | — | — | EP | claimed |
| EP-4489739-A2 | COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE USING COMBINATION OF A NITRODILATOR AND A NITROGEN OXIDE COMPOUND | Loma Linda University (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2024215633-A1 | METHOD OF DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | PrognostX Health Inc. (US) | 2024-10-17 | — | — | WO | claimed |
| US-20240335408-A1 | Soluble Guanylate Cyclase Activators for Cancer and Fibrosis Treatment | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2024-10-10 | — | — | US | claimed |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | NICOX S.A. (FR) | 2024-07-25 | — | — | US | claimed |
| EP-4373577-A1 | ACTRII PROTEINS AND USES THEREOF | Acceleron Pharma Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| US-11980618-B2 | Nitric oxide releasing phosphodiesterase type 5 inhibitor | NICOX S.A. (FR) | 2024-05-14 | — | — | US | claimed |
| WO-2009138165-A1 | SGC STIMULATORS, SGC ACTIVATORS AND COMBINATIONS THEREOF FOR THE TREATMENT OF HEARING IMPAIRMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-19 | — | — | WO | claimed |
| EP-2040691-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF 4-[((4-CARBOXYBUTYL)-{2-[(4-PHENETHYL-BENZYL)OXY]-PHENETHYL}AMINO)METHYL]BENZOIC ACID | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | claimed |
| WO-2008138483-A1 | sGC STIMULATORS, sGC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-20 | — | — | WO | claimed |
| WO-2008003414-A1 | AQUEOUS PHARMACEUTICAL FORMULATION OF 4-[((4-CARBOXYBUTYL)-{2-[(4-PHENETHYL-BENZYL)OXY]-PHENETHYL}AMINO)METHYL] BENZOIC ACID | BAYER HEALTHCARE AG (DE) | 2008-01-10 | — | — | WO | claimed |
| US-20050181066-A1 | Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | US | claimed |
| WO-2005042022-A2 | COMBINATION OF AN ACTIVATOR OF SOLUBLEGUANYLATE CYCLASE AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST | PFIZER LIMITED (GB) | 2005-05-12 | — | — | WO | claimed |
| US-20050059660-A1 | activators of soluble guanylate cyclase, and inhibitors of angiotensin converting enzyme such as benazepril; treatment of cardiovascular or metabolic disorders | PHARMACIA & UPJOHN COMPANY | 2005-03-17 | — | — | US | claimed |
| WO-2005011727-A1 | COMBINATION OF AN ACTIVATOR OF SOLUBLE GUANYLATE CYCLASE AND AN ACE-INHIBITOR FOR THE TREATMENT OF A CARDIOVASCULAR OR METABOLIC DISORDER | PFIZER LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| EP-1501605-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA Pharma AG (DE) | 2005-02-02 | — | — | EP | claimed |
| WO-2003090870-A1 | NOVEL USE OF GUANYLATE CYCLASE ACTIVATORS FOR THE TREATMENT OF RESPIRATORY INSUFFICIENCY | ALTANA PHARMA AG (DE) | 2003-11-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11980618-B2 | Nitric oxide releasing phosphodiesterase type 5 inhibitor | PDE5A, PDE3A, PDE3B | PTGER1 130/4885PTGER4 257/4885PTGER3 211/4885 |
| US-20260144798-A1 | Disruption of Vascular Smooth Muscle Relaxation by Carfilzomib May be the Primary Reason for CFZ-Induced Vascular Dysfunction | PDE5A, PRKG2, MAPKAPK5 | PTGER1 1419/4885PTGER4 2725/4885PTGER3 1084/4885 |
| US-20250281485-A1 | DIAGNOSIS AND/OR TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | NOX5, PDE5A, NOX1 | PTGER1 147/4885PTGER4 235/4885PTGER3 149/4885 |
| US-20240335408-A1 | Soluble Guanylate Cyclase Activators for Cancer and Fibrosis Treatment | GUCY1A1, GUCY1A2, GUCY1B1 | PTGER1 57/4885PTGER4 313/4885PTGER3 225/4885 |
| US-20240245684-A1 | NITRIC OXIDE RELEASING PHOSPHODIESTERASE TYPE 5 INHIBITOR | PDE5A, PDE3A, PDE6A | PTGER1 60/4885PTGER4 259/4885PTGER3 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.